| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2014-01-07 | Bind Therapeutics (USA - MA) | resignation |
Cancer - Oncology | Resignation | ||
| 2014-01-06 | RSVC Corporation (USA) Mymetics (Switzerland) | virosome vaccine | respiratory syncytial virus (RSV) infection | licensing |
Infectious diseases | Licensing agreement |
| 2014-01-06 | Lundbeck (Denmark) Ossianix (USA) | antibodies based on the shark VNAR structure and bispecific biopharmaceuticals | pain | R&D |
CNS diseases | R&D agreement |
| 2014-01-06 | Janssen Biotech, a J&J company (USA - NJ) - Capricor Therapeutics (USA - CA) | cell therapy program for cardiovascular applications, including CAP-1002 | licensing collaboration |
Cardiovascular diseases | Licensing agreement | |
| 2014-01-03 | Probiodrug (Germany) AstraZeneca (UK) | cyclin-dependent kinase 9 (CDK9) inhibitor program | sale |
Cardiovascular diseases - Inflammatory diseases | R&D agreement | |
| 2013-12-23 | AstraZeneca (UK) Cancer Research (UK) Cancer Research Technology (UK) | AZD2098 | kidney cancer | R&D |
Cancer - Oncology | R&D agreement |
| 2013-12-19 | Roche Nimblegen (USA - Switzerland) Kapa Biosystems (USA) | NGS target enrichment workflow solution | Technology - Services | Services contract | ||
| 2013-12-19 | Sanofi (France) Regeneron Pharmaceutical (USA - NY) American College of Cardiology (USA) | alirocumab (SAR236553/REGN727) | patients with heterozygous familial hypercholesterolemia (heFH), patients with primary hypercholesterolemia with elevated LDL-C | R&D |
Cardiovascular diseases - Genetic diseases - Rare diseases | Clinical research agreement |
| 2013-12-19 | Orion Corporation (Finland) Janssen Pharmaceuticals (J&J - USA) | alpha-2c adrenoceptor antagonists including a clinical phase compound ORM-12741 | Alzheimer\'s disease | licensing |
Neurodegenerative diseases | Licensing agreement |
| 2013-12-18 | Domain Therapeutics (France) Universite de Montreal (Canada) IRICoR (Canada) McGill University (Canada) | G-protein coupled receptors (GPCRs) biosensor technology | R&D |
Technology - Services | Licensing agreement | |
| 2013-12-18 | Merck KGaA, Merck Serono (Germany) Spanish National Cancer Research Centre (CNIO) (Spain) | inhibitors of the ataxia telangiectasia and Rad3-related (ATR) kinase | licensing |
Cancer - Oncology | Licensing agreement | |
| 2013-12-18 | Circuit Therapeutics (USA) Boehringer Ingelheim (Germany) | psychiatric disorders | R&D |
CNS diseases - Mental diseases | R&D agreement | |
| 2013-12-18 | Open Monoclonal Technology (USA) Roche (Switzerland) Genentech, a member of the Roche Group (USA - Switzerland) | OmniRat platform | Technology - Services | Licensing agreement | ||
| 2013-12-17 | Pluristem Therapeutics (Israel) Cha Bio&Diostech (South Korea) | PLX-PAD cells (PLacental eXpanded (PLX) cells) | peripheral artery disease, critical limb ischemia, intermediate claudication | collaboration |
Cardiovascular diseases | Licensing agreement |
| 2013-12-17 | BiogenIdec (USA - MA) Samsung Bioepis (South Korea) | anti-TNF biosimilar product candidates | rheumatoid arthritis, Crohn’s disease | commercialisation |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases | Commercialisation agreement |
| 2013-12-17 | Norgine (The Netherlands) Innovacell (Austria) | ICEF15 | faecal incontinence with sphincter weakness or damage | licensing |
Licensing agreement | |
| 2013-12-17 | ProBioGen (Germany) Emergent BioSolutions (USA) | AGE1.CR® Cell Line | licensing |
Technology - Services | Licensing agreement | |
| 2013-12-17 | Horizon Discovery (UK) Desktop Genetics (UK) | CRISPR design platform | R&D |
Technology - Services | R&D agreement | |
| 2013-12-17 | CMC Biologics (Denmark - USA) Oncosynergy (USA-France) | OS2966 monoclonal antibody program | development |
Cancer - Oncology | Production agreement | |
| 2013-12-17 | Pieris (Germany) Stelis Biopharma (India) | novel Anticalin®-based protein therapeutics, primarily focusing on ophthalmology | development |
Ophtalmological diseases | Development agreement |
